公开(公告)号：EP1957105A2

公开(公告)日：2008-08-20

申请号：EP06818915.8

申请日：2006-11-28

申请人： GlaxoSmithKline Biologicals S.A.

发明人： GARCON, Nathalie, Marie-Josephe ,  HANON, Emmanuel, Jules

IPC分类号： A61K39/29 ,  A61P31/12

CPC分类号： A61K39/0258 ,  A61K39/00 ,  A61K39/07 ,  A61K39/104 ,  A61K39/12 ,  A61K39/292 ,  A61K2039/545 ,  A61K2039/55544 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/57 ,  A61K2039/6037 ,  C07K2319/00 ,  C07K2319/55 ,  C12N2730/10134 ,  Y02A50/472 ,  Y02A50/474

摘要： The present invention provides a vaccine composition comprising a non-live vector which targets the MHC class I pathway derived from a bacterial toxin or an immunologically functional derivative thereof but excluding those which bind the Gb3 receptor complexed with at least one first antigen and further comprising at least one second antigen (which may be the same or different as the first antigen) and an adjuvant.

公开(公告)号：EP3565844B8

公开(公告)日：2023-04-12

申请号：EP18704101.7

申请日：2018-01-09

发明人： JENKINS, David ,  LAKEN, Haley A. ,  IM, Ellie ,  DIAZ, Allene ,  LU, Sharon

IPC分类号： C07K16/28 ,  A61P35/00

公开(公告)号：EP3468960A1

公开(公告)日：2019-04-17

申请号：EP17733530.4

申请日：2017-06-07

申请人： GlaxoSmithKline Intellectual Property Development Limited

发明人： AXTEN, Jeffrey ,  CHEUNG, Mui ,  DEMARTINO, Michael P. ,  EIDAM, Hilary Schenck ,  KETHIRI, Raghava Reddy ,  KALITA, Biswajit

IPC分类号： C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  C07D451/04 ,  C07D498/10 ,  C07D209/52 ,  C07D211/26 ,  C07D211/56 ,  C07D211/58 ,  C07D211/60 ,  C07D211/62 ,  A61K31/4468 ,  A61K31/46 ,  A61K31/454

公开(公告)号：EP2542261B1

公开(公告)日：2016-07-06

申请号：EP11705617.6

申请日：2011-03-01

申请人： Glaxo Group Limited

发明人： BHINDER, Tejinder, Kaur ,  FORD, Susannah, Karen ,  GERMASCHEWSKI, Volker ,  LEWIS, Alan, Peter ,  PEPYS, Mark, Brian

IPC分类号： A61K39/00 ,  C07K16/18

CPC分类号： C07K16/18 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

公开(公告)号：EP3011343A2

公开(公告)日：2016-04-27

申请号：EP14733732.3

申请日：2014-06-18

申请人： Glaxosmithkline Intellectual Property (No. 2) Limited

发明人： LOPEZ, Francisco

IPC分类号： G01N33/68

CPC分类号： G01N33/564 ,  C07K16/18 ,  C07K2317/20 ,  C07K2317/92 ,  G01N2333/4716 ,  G01N2333/96433 ,  G01N2333/988 ,  G01N2500/02 ,  G01N2500/20 ,  G01N2800/2821 ,  G01N2800/7042

摘要： The present invention relates to a CFI bioactivity assay designed to quantitatively measure (a) CFI bioactivity of plasma or other body fluids; and (b) bioactivity of CFI in plasma or other body fluids of a human patient afflicted by a disease that involves amyloid deposition in tissues, in particular Alzheimer disease, AMD, glaucoma, or beta-amyloid cataract formation.

摘要翻译： 本发明涉及设计用于定量测量（a）血浆或其他体液的CFI生物活性的CFI生物活性测定; 和（b）患有由组织中淀粉样蛋白沉积，特别是阿尔茨海默病，AMD，青光眼或β-淀粉样蛋白白内障形成的疾病所致的疾病的人类患者的血浆或其他体液中的生物活性。

公开(公告)号：EP2603522A1

公开(公告)日：2013-06-19

申请号：EP11743554.5

申请日：2011-08-12

申请人： GlaxoSmithKline Intellectual Property Development Limited

发明人： ARULANANTHAM, Haren ,  BATUWANGALA, Thil Dinuk ,  DE ANGELIS, Elena ,  ENEVER, Carolyn ,  LIU, Haiqun ,  SCHON, Oliver

IPC分类号： C07K16/18 ,  C12N15/13

CPC分类号： C07K16/18 ,  C07K16/2878 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/41

摘要： The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.

公开(公告)号：EP2582392A2

公开(公告)日：2013-04-24

申请号：EP11796557.4

申请日：2011-06-17

申请人： Human Genome Sciences, Inc.

发明人： WASSERMAN, Heather ,  CARLSON, Timothy ,  MIGONE, Thi-sau ,  DEVALARAJA, Madhav

IPC分类号： A61K39/395

CPC分类号： C07K16/2875 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/76

摘要： Methods of preventing, treating, and ameliorating asthma, allergen-induced respiratory symptoms, and/or an allergic or inflammatory condition of the lung or respiratory system in a patient by administering B Lymphocyte Stimulator antagonists are provided. In addition, a method of reducing total serum IgE levels in a patient suffering from asthma, and/or an allergic or inflammatory condition of the lung or respiratory system by administering B Lymphocyte Stimulator antagonists is provided. A method of treating, preventing or ameliorating an allergen-induced airway hyper responsiveness or increase in mucus-containing cells and/or mucus accumulation or production in the airway epithelium of a patient by administering B Lymphocyte Stimulator antagonist is also provided.

公开(公告)号：EP2542261A1

公开(公告)日：2013-01-09

申请号：EP11705617.6

申请日：2011-03-01

申请人： Glaxo Group Limited

发明人： BHINDER, Tejinder, Kaur ,  FORD, Susannah, Karen ,  GERMASCHEWSKI, Volker ,  LEWIS, Alan, Peter ,  PEPYS, Mark, Brian

IPC分类号： A61K39/395 ,  A61P25/28 ,  C07K16/18

CPC分类号： C07K16/18 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

摘要： The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.

公开(公告)号：EP2086582B1

公开(公告)日：2012-11-14

申请号：EP07821111.7

申请日：2007-10-10

申请人： GlaxoSmithKline Biologicals s.a.

发明人： BALLOU, William Ripley Jr. ,  HANON, Emmanuel Jules

IPC分类号： A61K39/39 ,  A61P31/16 ,  A61K39/145 ,  A61K39/295

CPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K39/39 ,  A61K2039/5252 ,  A61K2039/55566 ,  A61K2039/70 ,  C12N2760/16134 ,  C12N2760/16234 ,  Y02A50/41

摘要： The present invention provides an immunogenic composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil in water emulsion, wherein said oil in water emulsion comprises 0.5 - 10 mg metabolisable oil, 0.5 - 11 mg tocol and 0.1 - 4 mg emulsifying agent, per human dose.

公开(公告)号：EP1663243B1

公开(公告)日：2009-02-18

申请号：EP04764689.8

申请日：2004-08-31

申请人： GLAXO GROUP LIMITED

发明人： VAN SCHIE, Dirk, Marinus J., GlaxoSmithKline

IPC分类号： A61K31/513 ,  A61K9/56 ,  A61K9/30 ,  A61P9/10

CPC分类号： A61K9/2077 ,  A61K9/2846 ,  A61K9/2886 ,  A61K31/513

摘要： The present invention provides enteric polymer coated tablet formulations for oral administration which comprise a phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2) inhibitor, processes for preparing such formulations and their use in therapy, in particular the treatment of atherosclerosis.